OTC Stock Review: Award Winning Small Cap Stock Picks Since 2004

 

OTC Stock Review Like us on FaceBook! Follow us on Twitter! Connect on LinkedIn

office (404) 856-9157

toll-free (866) 692-6847

email info@otcstockreview.com


OTC Stock Review: Award Winning Small Cap Stock Picks Since 2004

Stocks In Motion

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack® System, which has been used in diagnostics for almost 20 years. The FastPack menu includes tests for cancer, men’s health, hormone function, vitamin D status and antibodies against SARS-CoV-2. The Company’s cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F and STARS™.  ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects.

The foundational aptamer of ALAN, AS1411, is also being studied for use in treating or even preventing viral-based infectious diseases, including COVID-19. RAS-F is a family of RAS oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device product candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen’s only products that are currently commercially available are its FastPack System diagnostic instruments and test kits. Qualigen’s facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC, or Sekisu. Read more about Qualigen Therapeutics, Inc. in our Report.


 

QSAM Bioscience, Inc. (QSAM) holds the worldwide license for CycloSam (Samaium-153 DOTMP), a clinical stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. This isn’t just bone cancer. This drug could be used to treat OsteoSarcoma and Bone Metastasis. There has been no new treatment for OsteoSarcoma in the last 40 years. Forget about the fact that this is a billion dollar market. OsteoSarcoma and Bone Metastasis are both very common in Ewing Sarcoma, which is a cancerous tumor that grows in the bones, or in the tissue around bones, of children. The result is often amputation of the affected limb. QSAM could change this.

SAM is expecting to start the FDA approval process for CycloSam after the first of the year. The market cap on this company is much lower than just about every other company in the FDA approval process. QSAM will be looking for FDA approval on CycloSam as a chelate vehicle that carries the drug that can stop the growth of a tumor to the site of the growth.  Read more about QSAM Bioscience in our Special Report.


Renavotio, Inc. (OTCQB: RIII) is a holding company with internationally-recognized businessman, veteran entrepreneur and original Shark Tank investor, Kevin Harrington, on its Advisory Board. RIII is an infrastructure play and the Company intends to acquire infrastructure companies with Personal Protection Equipment sales and manufacturing, utility construction, consulting/operational agreements with small towns or county CO-OPS that operate their own water and sewer systems, providing long-term savings, utilizing smart-utility monitoring, and dedicated engineering and service personnel.

These platforms capture utility data from hand-held GPS devices or in-place sensors, with planned use of drones to identify waste contamination, leak detection, and topographic underground utility installation planning.  The infrastructure business is big business and there are a slew of small to mid-sized companies for RIII to acquire. According to a June 9, 2020 article in Forbes, "The $3.6 trillion annual global infrastructure market is one of the most important, complex, challenging - and potentially rewarding - markets in the world.  Read more about Reavotio, Inc. in our Special Report.


 

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) isn't just another CBD stock. RTSL is a CBD stock with some serious potential. First, let's look at the basics. RTSL is a fully-reporting company with the U.S. Securities and Exchange Commission. This innovative biotech company specializes in aerosol delivery of legal cannabinoids to the systemic blood stream though the pulmonary route of administration, which means you inhale it into your lungs. RTSL's main product is the Rxoid metered dose inhaler (MDI). The Rxoid MDI shares many similar physical characteristics to an asthma inhaler and works the same way by delivering medication directly to a user's blood stream through the pulmonary tract.

Rapid Therapeutic Science Laboratories, Inc. started trading publicly around the end of 2019 and is the low-float play most investors are looking for. With 200,000,000 authorized, RTSL has 156,856,000 issued and outstanding, as of May 6, 2020. Of the 156,856,000 issued and outstanding, 141,000,000 are restricted, 15,856,000 shares are unrestricted, and only 26,000 (not a typo) shares are held in DTC. Read more about Rapid Therapeutic Science Laboratories, Inc. in our Report.


 

Ealixir Inc. (OTC: EAXR) is an artificial intelligence company specializing in the management and protection of digital identity and computer technology rights. By providing individuals and businesses with the ability to control and edit information posted on the internet, EAXR helps its customers manage their online identity. The Company provides its customers the opportunity to choose the links that appear when someone searches for them on an internet search engine.

Based in Milan, Italy, EAXR currently has offices in 25 countries, including 18 operational offices and 7 representative offices. EAXR has provided service to over 500 clients worldwide, none of whom have exercised their right to have their application fee refunded. On an unaudited basis, EAXR generated annual revenues of $5,650,350 and net profits of $1,171,728 for the fiscal year ended December 31, 2019. Revenues for the fiscal year ending year ending December 31, 2018 were $1,346,872 with a net loss of $19,835.  Read more about Ealixir Inc. in our Special Report. 


 

Ring Energy, Inc. (NYSEAmerican: REI) is a Midland, Texas-based oil and gas exploration, development, and production company with current operations in the Permian Basin of West Texas, which is recognized as the top producing oil basin in North America. Founded in 2012, the experienced management team has aggressively sought to acquire select properties in the Permian Basin with development opportunities for future years. As of 12/31/18, the company has, through exploitation and acquisitions, increased their proved reserves to an estimated 36.6 million BOE’s (barrel of oil equivalents). CEO Kelly Hoffman cut his teeth in the Permian Basin. He started out there in 1975 with Amoco Production Company.

In the early 1990’s, Mr. Hoffman co-founded AOCO and drilled 60 wells in the Fuhrman Mascho field in Andrews, Texas. After 18 months and a 600% increase in revenue, AOCO sold the properties to Lomak (Range Resources). He did the same thing again in 1999 when he acquired 12,000 acres in Lubbock and Crosby counties. After drilling and completing 19 successful wells, he sold his interest in the property to Arrow Operating Company. My take is the management team at Ring Energy knows the Permian Basin very well.  Read more about Ring Energy, Inc. in our Special Report.


 

ImageWare Systems, Inc. (OTCQB: IWSY) is a top developer of mobile and cloud-based multi-modal biometric identity management solutions, providing biometric, secure credential, and law enforcement technologies. After a bold start evolving silver halide photography into digital images, ImageWare built the first statewide digital booking platform for the United States law enforcement in 1998. Since then, ImageWare has evolved into the largest holder of multimodal biometrics, managing over 100 million identities daily.

With vast experience in the government sector, ImageWare is democratizing biometrics by offering defense-grade identity and authentication solutions to the masses. By identifying the person, not a device, and never disclosing Personally Identifiable Information (PII), ImageWare is giving populations around the globe access to their important data. The company's biometric product line is scalable for global deployment. ImageWare's biometric product line includes a multi-biometric engine. This engine is hardware and algorithm independent. This allows the enrollment and management of unlimited population sizes. ImageWare Systems is based in San Diego, California.  Read more about ImageWare Systems (IWSY) in our Special Report.

Information and Resources

FINRA's Daily List is a list of new issues, deleted issues, symbol and name changes, and other corporate actions for OTCBB and other-OTC securities.  Read more.

OTC Markets daily list of Corporate Actions includes Symbol Changes, Marketplace/Tier Changes, Caveat Emptor Status Changes, Venue Changes, Ex-Dividends, Splits, Scheduled Dividends, Company Name Changes, Symbol & Name Changes, Suspensions/Halts, Deletions, Anticipated Piggybacks, and Piggyback Qualified issues.  Read more.

OTCQX, OTCQB, OTC Pink, and Other OTC Most Active, biggest Advancers, and Biggest Decliners.  Read more.

50 Day Bouncers - Stocks that have recently bounced up from, or near, the 50 Day Moving Average.  Read more.

The Truth About Trading For A Living (Tips for people getting started)  Read more.

How to Read a 10-K from the SEC's Office of Investor Education and Advocacy Read more.
The Grass Isn’t Always Greener — FINRA's guide to chasing return in a challenging investment environment. Read more.

A Traders Quick Guide to Position Sizing  -  by Steve Burns  Read more.


Recent Articles

Big-Name Executives and Celebrities Open Up Opportunities for Retail Investors by Investing in Psychedelic Treatment as a Means of Addressing Mental Health Crisis
ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- One day we are all going to look back at psychedelic stocks and realize the Grateful Dead was right. What a long strange trip it's been! Psychedelic stocks...

December 08, 2020

Trends in Psychedelic Drugs Research and Four Stocks You Should Know About
OTCStockReview.com News Commentary ATLANTA, Oct. 16, 2020 (GLOBE NEWSWIRE) -- 2020 has been quite a year, but hidden among the carnage is great news about advances in research on psychedelic...

October 16, 2020

U.S. Small Cap Stocks Could Outperform The Market During The Recovery And Here Are Four Stocks You Need To Know About
ATLANTA, July 22, 2020 (GLOBE NEWSWIRE) -- According to Premier Miton Fund Manager Nick Ford in a recent CNBC’s “Squawk Box Europe” interviewi, U.S. small cap stocks are set to outperform the...

July 22, 2020

Four CBD Stocks For The Last Half Of 2020
ATLANTA, June 24, 2020 (GLOBE NEWSWIRE) -- CBD products have gone mainstream and are now available in major retailers like CVS, Walgreens, and Kroger. Over the past few years many companies have...

June 24, 2020

Listen Up, These Hearing Aid Stocks Could Help Rebuild Your Portfolio
OTCStockReview.com News Commentary ATLANTA, April 01, 2020 (GLOBE NEWSWIRE) -- Over the past three or four months, the news coming out of Congress has been all about the coronavirus pandemic,...

April 01, 2020

Tremendous Opportunities in Psychedelic Research are Beginning to Garner Investor Attention
OTCStockReview.com News Commentary ATLANTA, Jan. 22, 2020 (GLOBE NEWSWIRE) -- There is an uptrend in the research of psychedelic substances for treating mental illnesses like addiction,...

January 22, 2020

OTC Stock Review Features Four CBD Stocks for 2020
ATLANTA, GA, Nov. 21, 2019 (GLOBE NEWSWIRE) -- CBD products are becoming extremely popular as consumers discover the benefits of cannabidiol in industries like cosmetics, health products, food and...

November 21, 2019

My Case For Going Long Oil Stocks  Read more.

Exclusive Snapchat: What You Need To Know  Read more.

Exclusive Snap, Inc.: Why I'm Out On The Sidelines Read more.

Cannabis Sector Gains Traction On President Trump’s Positive Comments On State’s Rights  Read more.

Trump Deregulation Creates Attractive Opportunities In Oil And Gas Companies Read more.




Get Our Award Winning Small-Cap Stock Picks Free!

* required

*







*



Email & Social Media Marketing by VerticalResponse

Social Media

 



As Seen On



IHUB

MarketWatch





































































Investor Cheat Sheets